Document Detail

The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma.
MedLine Citation:
PMID:  10727305     Owner:  NLM     Status:  MEDLINE    
We have undertaken a retrospective analysis of all positron emission tomography (PET) scans carried out at St Thomas' Hospital, London, since 1994 to establish the sensitivity and specificity of this radiologic technique in cutaneous malignant melanoma. In particular, we have identified those patients with primary cutaneous malignant melanoma in whom PET scanning revealed in-transit or regional spread to nodes and those patients with known regional spread in whom PET scanning revealed distant metastases. We defined our false-negative results as a negative scan result with positive histology or subsequent clinical progression of disease. False-positive results were defined as a suspect scan with negative histology or no subsequent progression of disease. PET scanning had an overall sensitivity of 78% and specificity of 87%; however, subset analysis (M. D. Anderson staging system) showed a sensitivity of 50% for stage I disease (34 patients and 35 scans) and 33% for stage II disease (9 patients and 9 scans) with specificities of 87% and 100%, respectively. For stage III disease (16 patients and 17 scans), PET showed a sensitivity of 93% and specificity of 50%. Overall, 35% of patients with true-positive scans had their disease restaged. We can conclude therefore that PET is valuable as a staging procedure in patients with known regional spread but is suboptimal in the prediction of outcome in stage I or stage II disease.
K M Acland; M J O'Doherty; R Russell-Jones
Related Documents :
19121745 - Kienböck's disease.
21087395 - Radical prostatectomy for ct3-4 disease: an evaluation of the pathological outcomes and...
25368745 - An overview of eosinophilic esophagitis.
179695 - Current status of treatment of gestational trophoblastic disease.
2194945 - Peptic ulcer disease in the elderly.
17965655 - Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  42     ISSN:  0190-9622     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-05-02     Completed Date:  2000-05-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  606-11     Citation Subset:  IM    
Skin Tumour Unit, St John's Institute of Dermatology, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fluorodeoxyglucose F18 / diagnostic use
Melanoma / radionuclide imaging*,  secondary*
Middle Aged
Neoplasm Staging
Radiopharmaceuticals / diagnostic use
Retrospective Studies
Sensitivity and Specificity
Skin Neoplasms / pathology,  radionuclide imaging*
Tomography, Emission-Computed*
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blue in the skin.
Next Document:  Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular...